Cutaneous Reactions to Vaccination: Clinical and Histopathological Features

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 3288

Special Issue Editors

Section of Dermatology and Venereology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari “Aldo Moro”, 70124 Bari, Italy
Interests: dermatology; tricology; inflammatory cutaneous diseases; skin tumors; dermoscopy; trichoscopy

Special Issue Information

Dear Colleagues,

The advent of anti-SARS-CoV-2 mRNA vaccines has drastically reduced the morbidity and mortality associated with COVID-19, allowing a return to rather normal living conditions in a small number of months. Since the beginning of the vaccination campaign, vaccines have proven to be extremely effective in reducing complications during the disease, and there have been various reports of adverse events which, however, have been much lower than the benefits of vaccination. In this Special Issue, we intend to collect original articles, case reports, case series, reviews, and possible comments on this topic, with the hope of hosting scientific contributions that can stimulate discussion and herald new advances in this area.

Dr. Gerardo Cazzato
Dr. Francesca Ambrogio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • adverse reactions
  • SARS-CoV-2
  • cutaneous manifestations
  • dermatology

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

3 pages, 196 KiB  
Editorial
Cutaneous Manifestations of SARS-CoV-2, Cutaneous Adverse Reactions to Vaccines Anti-SARS-CoV-2 and Clinical/Dermoscopical Findings: Where We Are and Where We Will Go
by Gerardo Cazzato
Vaccines 2023, 11(1), 152; https://doi.org/10.3390/vaccines11010152 - 10 Jan 2023
Cited by 2 | Viewed by 975
Abstract
From the very first months of the pandemic, it became apparent that a variety of skin reactions could occur during COVID-19 disease, starting with ‘erythema-pernio’-type lesions, similar to chilblains [...] Full article

Review

Jump to: Editorial

20 pages, 710 KiB  
Review
Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review
by Florica Șandru, Andreea-Maria Radu, Aida Petca, Mihai Cristian Dumitrașcu, Răzvan-Cosmin Petca and Alexandra-Maria Roman
Vaccines 2024, 12(3), 228; https://doi.org/10.3390/vaccines12030228 - 23 Feb 2024
Viewed by 767
Abstract
Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, [...] Read more.
Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology. Full article
Show Figures

Figure 1

22 pages, 941 KiB  
Review
Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters
by Emmanouil Karampinis, Myrto-Maria Papadopoulou, Kleoniki Chaidaki, Konstantina-Eirini Georgopoulou, Stavroula Magaliou, Angeliki Viktoria Roussaki Schulze, Dimitrios P. Bogdanos and Efterpi Zafiriou
Vaccines 2024, 12(2), 178; https://doi.org/10.3390/vaccines12020178 - 09 Feb 2024
Cited by 1 | Viewed by 1064
Abstract
The diverse patient population and widespread vaccination in the COVD-19 era make vaccine-triggered episodes of psoriasis an ideal model of exposome research. This scenario explores the fine balance between protective and exacerbating factors, providing insights into the complex relationship between environmental exposure and [...] Read more.
The diverse patient population and widespread vaccination in the COVD-19 era make vaccine-triggered episodes of psoriasis an ideal model of exposome research. This scenario explores the fine balance between protective and exacerbating factors, providing insights into the complex relationship between environmental exposure and psoriasis immunopathogenesis when a trigger appears, such as that of the hyperinflammatory state induced by the COVID-19 vaccine. Analyzing interactions between vaccine-induced phenomena and exposome parameters may provide clinically relevant information important for personalized medicine decision-making. We performed a literature review seeking patients with plaque psoriasis flares or new onset or change in plaque psoriasis into another psoriasis subtype, such as pustular or erythrodermic flare, focusing on the inner and external exposome traits of patients. We identified 71 patients with plaque psoriasis flares, 12 patients with new-onset psoriasis, and 17 with plaque psoriasis subtype change, and assessed the COVID-19 vaccine-induced plaque psoriasis in terms of clinical presentation, post-vaccination flare period and treatment status, as well as inner exposome parameters (genomics, oxidative stress, hormonal impact due to gender, aging, skin color) and external parameters (UV, infectomics). Novel data on psoriasis flares following COVID-19 vaccination are primarily obtained by combining exposome and vaccine-triggered episode features and characteristics and comparing them with similar psoriasis flares unrelated to COVID-19 vaccination. Full article
Show Figures

Figure 1

Back to TopTop